Skip to main content
OpenTrials
Completed

NCT Number: NCT00823381

Effect of Resvida, a Comparison With Calorie Restriction Regimen

The purpose of this study is to compare the effects of the antioxidant "resveratrol" to a diet intervention (Calorie Restriction) to determine how each of them affects the following: gene expression profile, cholesterol (lipids), how well the hormone insulin works to control your blood sugar, and other blood and tissue markers of metabolic and cardiovascular health.

Resveratrol is found in grape skin, wine, peanuts, and mulberries and is thought to have health benefits such as improving fat metabolism, insulin action, and possibly extending lifespan. Resvida™ is the name for the dietary supplement containing the natural antioxidant "resveratrol". Resvida™ will be supplied by DSM Nutritional Products, Ltd.

Resvida™ is considered a dietary supplement, and therefore it is not an approved drug by the Food and Drug Administration (FDA). It is regulated like a food. The U.S. Food and Drug Administration does not strictly regulate herbs and dietary supplements. The makers of Resvida™ make no claim that this supplement is meant to treat any ailment.

Calorie restriction (CR) is a low calorie diet (about 30% fewer calories than the American Dietetic Association (ADA) recommends). Calorie restriction has also been linked to health benefits (enhanced cardiovascular and metabolic health) and an extended lifespan.

This study is designed to compare the health benefits of both resveratrol and CR and to determine if resveratrol mimics some of the health benefits shown with CR.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Post-menopausal females (at least 1 year since last spontaneous menstrual bleeding)
  • Caucasian
  • Weight (defined as BMI): ≥ 20kg/m2 and < 30 kg/m2.
  • Subjects willing and able to give written informed consent and to understand, to participate and to comply with the study requirements with specific agreement to a measurement of global gene expression profiles
  • Subjects with the ability to comprehend and complete forms in English
  • Subjects who are likely to comply with study procedures
  • Subjects who are willing to be assigned to the Resveratrol or CR or Placebo intervention

Exclusion criteria

  • History of serious or unstable medical or psychiatric disorders (e.g. diabetes, metabolic, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, immune, hepatic, renal, urologic, musculoskeletal, or cancer) that, in the opinion of the investigator, would make the candidate ineligible for the study.
  • History of major abdominal, thoracic or non-peripheral vascular surgery within one year prior to the randomization date
  • Subjects with any allergic reaction or sensitivity to grape products or any component of the test article
  • Subjects who are allergic to lidocaine
  • Subjects currently on a low-calorie diet, a weight control or maintenance program, or those who practice a vegetarian or vegan diet
  • Subjects who engage in programmed exercise > 2 hours total per week
  • Subjects who are smoking or stopped smoking within the past 6 months
  • Subjects who have lost or gained >5 kg over the past six months
  • Subjects on any other clinical trial or experimental treatment within the past 3 months
  • Intake of dietary supplements except vitamins and minerals
  • Unwilling to restrict high resveratrol-containing foods
  • Current alcohol consumption >20 grams/day
  • Current use of the following medications: weight loss medications (prescription or over-the-counter), beta-blockers, steroids, anticoagulants, any other medications that, in the opinion of the investigator, may compromise the validity or safety of the study.

Treatment and study plan

Resveratrol

Dietary Supplement

one pill of resveratrol (Resvida™) 75 mg once a day with breakfast

Other names: Resvida™

Placebo

Other

one placebo pill taken once a day with breakfast

Calorie Restriction

Behavioral

supervised calorie restriction diet: 30% reduction in caloric intake

Primary outcomes

  1. global skeletal muscle gene expression profile

    Time frame: three months

Secondary outcomes

  1. insulin sensitivity

    Time frame: three months

  2. intrahepatic triglyceride content, body composition

    Time frame: three months

  3. blood lipid levels, markers of inflammation and plasma hormones

    Time frame: three months

  4. safety and tolerability

    Time frame: three months

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Collaborators

  • dsm-firmenich Switzerland AG

Registry information

Official study title

Effect of Resvida(tm) Dietary Supplementation on Muscle Gene Expression: A Comparison With Calorie Restriction Regimen

Acronym: Resvida

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Jan 15, 2009
Registry last updated
Dec 10, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.